Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
MJFF Publications
Donate
Access Resources

MJFF Publications

The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.

 From
To
  • Default content image

    LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

    Learn more
  • Default content image

    The Michael J. Fox Foundation’s Efforts to Understand the Relationship between GBA1 and Alpha-Synuclein through the Development and Characterization of Preclinical Models

    Heterozygous mutations in the GBA1 gene--which encodes for lysosomal glucocerebrosidase (GCase)--are the most common genetic risk factor for Parkinson’s disease (PD). In addition, decreased GCase…
    Learn more
  • Default content image

    The Michael J. Fox Foundation’s Efforts to Develop New Tools for Understanding LRRK2 Biology and the Role of LRRK2 in Parkinson’s Disease Pathology

    As the greatest known genetic contributor to Parkinson's disease (PD), the leucine-rich repeat kinase 2 (LRRK2) gene and protein are targets of interest for Parkinson’s disease research and…
    Learn more
  • Default content image

    Characterization of a humanized A53T alpha-synuclein (aSyn A53T KI) and alpha-synuclein KO (aSyn KO) models

    Mutations and multiplications in the SNCA gene encoding the alpha-synuclein protein are linked to an autosomal dominant form of Parkinson’s disease (PD). One such mutation is the alanine-to-threonine…
    Learn more
  • Default content image

    The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Antibody Tools for Investigating Rab Molecular Biology

    A field-wide challenge in Parkinson’s disease (PD) research is a general lack of availability for high-quality, reproducible, and readily accessible preclinical research tools. To address these…
    Learn more
  • Default content image

    Cell Line Resources from Parkinson’s Progression Markers Initiative (PPMI) Participants

    The Parkinson’s Progression Markers Initiative (PPMI) is a longitudinal observational study conducted at over thirty international sites that collects data and biospecimens from idiopathic Parkinson…
    Learn more
  • Default content image

    LRRK2 Detection in PBMC Consortium

    The “LRRK2 Detection in PBMC Consortium” is a pre-competitive collaboration between MJFF and select industry partners with the goal of optimizing the measurement of pLRRK2 in human PBMCs. MJFF…
    Learn more

Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.

 From
To
  • Default content image

    Alpha-Synuclein: A Therapeutic Target and Potential Biomarker in Parkinson's Disease

    A detailed discussion of our current understanding of alpha-synuclein biology and the ongoing research and development surrounding its role in Parkinson's disease.
    Learn more
  • Default content image

    Diagnosis and Management of Neurodegenerative Atypical Parkinsonism

    A detailed consideration of the neurodegenerative diseases that can cause parkinsonism including dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP)…
    Learn more
  • Default content image

    Deep Brain Stimulation and Magnetic Resonance-guided Focused Ultrasound

    A review of innovations in surgical Parkinson's disease treatments, inlcuding deep brain stimulation and magnetic resonance-guided focused ultrasound.
    Learn more
  • Default content image

    Dystonia and Parkinson's Disease

    An exploration of the various manifestations of dystonia in the context of Parkinson's disease.
    Learn more
  • Default content image

    Levodopa 2.0: New Strategies to Even Out the Peaks and Valleys

    A discussion on the latest in new formulations and supplemental therapies of levodopa.
    Learn more
  • Default content image

    Dementia with Lewy Bodies: In the News and in the Clinic

    A practical review of the diagnosis and management of dementia with Lewy bodies.
    Learn more

Michael J. Fox Foundation publications supported through our OAP program.

We believe that the results of all MJFF-funded research should be promptly published and broadly disseminated to accelerate innovation and foster collaboration toward our shared goal of new treatments and cures for Parkinson’s disease. 

Request open access coverage funds for your MJFF project here

 From
To
  • Default content image

    Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression

    Parkinson's disease (PD) diagnosis relies primarily on clinical evaluation due to lack of validated tests and biomarkers. DaTscan imaging has been used to distinguish psychogenic and drug-induced…
    Learn more
  • Default content image

    Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor

    Neuropathological staging studies have suggested that tau pathology spreads through the brain in Alzheimer's disease (AD) and other tauopathies, but it is unclear how neuroanatomical connections,…
    Learn more
  • Default content image

    Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model

    Multiple mutations have been described in the human GBA1 gene, which encodes the lysosomal enzyme beta-glucocerebrosidase (GCase) that degrades glucosylceramide and is pivotal in glycosphingolipid…
    Learn more
  • Default content image

    Fyn knockdown prevents levodopa-induced dyskinesia in a mouse model of Parkinson's disease

    Dopamine replacement by levodopa is the most widely used therapy for Parkinson's disease (PD), however patients often develop side effects, known as levodopa-induced dyskinesia (LID), that usually…
    Learn more
  • Default content image

    Video-based Parkinson’s disease assessments in a nationwide cohort of Fox Insight participants

    Introduction: Parkinson's disease (PD) research is hampered by slow, inefficient recruitment and burdensome in-person assessments that may be challenging to conduct in a world affected by COVID-19…
    Learn more
  • Default content image

    α-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease

    Background: Extracellular vesicles are small vesicles that are released from many cells, including neurons. α-Synuclein has recently been described in extracellular vesicles derived from the central…
    Learn more
  • Default content image

    Hispanic perspectives on Parkinson's disease care and research participation

    Background: Hispanics are under-represented in Parkinson's disease (PD) research despite the importance of diversity for results to apply to a wide range of patients. Objective: To investigate the…
    Learn more
Female researcher pipetting in lab.

Breaking Research Updates

Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.

Read Research News
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.
Here. Until Parkinson's isn't.
Join us as we work to find a cure for the 6 million people worldwide living with Parkinson's.
 
 
 
 
Month
Day
Year